ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Doxorubicin-based combination chemotherapy for desmoid tumors

Doxorubicin-based combination chemotherapy for desmoid tumors
Regimen Number of patients Duration of therapy (cycles) Response Duration of response Author; year
DOXO plus DTIC 11* 2 to 10 (median 5)

2 CR

4 PR

1 MR

2 SD		 29 to 235 months Patel S; 1993
DOXO plus DTIC 5 4 to 6 (median 5) preoperatively

2 pCR

3 PR		 21 to 72 months Goepfert H; 1982
DOXO plus DTIC plus meloxicam 7 4 to 5 (median 5)

3 CR

4 PR		 32.5 to 107.5 (median 74) Gega M; 2006
DOXO plus DTIC (7 cycles) followed by CARBO plus DTIC 5 6 to 19

1 CR

3 PR

1 SDΔ		 10 to 30 months Schnitzler M; 1997
DOXO plus Cy, or IF plus VP-16, or IF plus VP-16 plus MITO plus DOXO plus CIS 7 2 to 8 (median 6) 3 OR◊ 3 to 180 months Okuno S; 2003
DOXO: doxorubicin; DTIC: dacarbazine; CR: complete response; PR: partial response; MR: minor response; SD: stable disease; pCR: pathologic complete response; CARBO: carboplatin; Cy: cyclophosphamide; IF: ifosfamide; VP-16: etoposide; MITO: mitomycin; CIS: cisplatin; OR: objective response; NED: no evidence of disease.
* 9 out of 11 patients were evaluable; 2 patients were treated in the 1970s and could not be evaluated objectively but were reported to have responses that enabled the resection of axillary and pelvic disease.
¶ All patients received chemotherapy preoperatively, only 1 patient recurred after surgery at 21 months. All others remained NED.
Δ Patient progressed rapidly after cessation of chemotherapy.
◊ All patients on chemotherapy showed some form of clinical benefit, such as OR or SD, or symptomatic improvement.
Graphic 71589 Version 3.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟